1. Home
  2. MLYS vs PAX Comparison

MLYS vs PAX Comparison

Compare MLYS & PAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

N/A

Current Price

$15.41

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Logo Patria Investments Limited

PAX

Patria Investments Limited

N/A

Current Price

$9.54

Market Cap

1.8B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
MLYS
PAX
Founded
2019
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.8B
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
MLYS
PAX
Price
$15.41
$9.54
Analyst Decision
Strong Buy
Buy
Analyst Count
11
6
Target Price
★ $45.22
$14.83
AVG Volume (30 Days)
★ 1.8M
1.5M
Earning Date
11-04-2026
11-03-2026
Dividend Yield
N/A
★ 6.76%
EPS Growth
★ 37.43
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$13.22
Revenue Next Year
N/A
$9.41
P/E Ratio
★ N/A
$25.65
Revenue Growth
N/A
N/A
52 Week Low
$15.33
$9.03
52 Week High
$47.65
$17.80

Technical Indicators

Market Signals
Indicator
MLYS
PAX
Relative Strength Index (RSI) 28.91 35.71
Support Level N/A N/A
Resistance Level $31.19 $11.74
Average True Range (ATR) 1.42 0.42
MACD -0.40 -0.14
Stochastic Oscillator 6.21 14.26

Price Performance

Historical Comparison
MLYS
PAX

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About PAX Patria Investments Limited

Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.

Share on Social Networks: